Issue 36


Termsheet 36

Download Request

Insight into Biosimilars: Market Landscape and Key Success Factors

Whilst the Biosimilars market represents a massive commercial opportunity, the landscape is quite complex, with multiple dynamics at play. Competition is high, and research proves that there is a strong correlation between market entry order and market uptake.

How do companies with Biosimilars assets realise their value and stand out from the competition?

As experts in the Biosimilars space, PharmaVentures provides insight in this new white paper.

 

 

Insight into Biosimilars: Market Landscape and Key Success Factors

Download Request

 

How Your Pricing and Reimbursement Strategy Affects Your Deal Making Success

PharmaVentures Podcast Series, Edition 2

 


How Your Pricing and Reimbursement Strategy Affects Your Deal Making Success

 


Hosted by Adrian Dawkes

Listen as PharmaVentures’ Pricing and Market Access expert, Ralph Hughes, recommends elements of a robust plan to help you achieve the best pricing and market access for your drug, and to give you the increased confidence to strengthen your position during deal making negotiations.

 

How Your Pricing and Reimbursement Strategy Affects Your Deal Making Success

Download Request

 

If you would prefer to read the transcript of the podcast please email: enquiries@pharmaventures.com

 

About the Presenter:

 

Adrian Dawkes is a Managing Director at PharmaVentures and has been with the company since 2007. Adrian has led multiple consultancy, licensing and M&A mandates.

 

During his professional career, Adrian has significant multi-discipline expertise spanning research and development through to sales, marketing and business development. Adrian has over 30 years’ experience in the pharmaceutical, biotechnology and consultancy services sectors. Adrian holds a BSc in Biochemistry and a PhD in Immunochemistry.

 

About the Interviewee:

 

Ralph Hughes is a Vice President at PharmaVentures with experience in Pricing and Market Access and Commercial and Business Development.

 

He has held various roles in the pharmaceutical industry. For Mundipharma, he developed the commercial and market access strategy for development and launch assets. At Pfizer, he developed market access and pricing strategies across the globe and across multiple disease areas for both early, late stage and in-market assets. He has delivered marketing campaigns, global forecasts, HTAs, pricing strategies, real world data studies, and economic models; through this, Ralph has a deep understanding of what it takes to commercialise an asset in the pharmaceutical industry. He holds a MSc in Public Health and Health Economics from the London School of Hygiene and Tropical Medicine and a BSc in Biomedical Sciences from Newcastle.

 

PharmaVentures’ new Vice President recruited to lead Pricing and Market Access practice

Ralph Hughes joins the corporate advisory team to support clients in bringing their products to market

London, UK, 27 September 2022: PharmaVentures is pleased to announce the appointment of Ralph Hughes as Vice President to lead its Pricing and Market Access practice.

Ralph has built extensive experience in Pricing and Market Access, and also in Commercial assessment, through his various roles in the pharmaceutical industry. For Mundipharma, he was responsible for the access and commercial launch strategy for key brands and for developing the commercial assessments for potential assets. At Pfizer, he developed market access and pricing strategies globally and across multiple disease areas for early-stage and in-market assets. He has developed marketing campaigns, forecasts, Health Technology Assessments, price guidance, real world data studies, market research and economic models.

Ralph developed economic models for NICE’s clinical guidelines programme. He holds a MSc in Public Health and Health Economics from the London School of Hygiene and Tropical Medicine, and a BSc in Biomedical Sciences from Newcastle.

Through his career to date, Ralph has developed a strong understanding of what it takes to overcome access hurdles and to commercialise a novel therapeutic.

Fintan Walton, Founder and CEO of PharmaVentures, said, “We are delighted to welcome Ralph to the PharmaVentures team. Many of our clients need high-quality pricing and market access guidance that will strengthen their narrative and position in development and deal making and we are pleased to support them in this crucial area.

– Ends –

For further information, please contact:

Lisa Holloway
Senior Marketing Manager
Phone: +44 (0) 1865 332700
lisa@pharmaventures.com

Distributed by PR Newswire (Cision)

About PharmaVentures

PharmaVentures is a premier transaction advisory firm and a leading international company in partnering, M&A deals and strategic alliances. For over 30 years, PharmaVentures has acted as advisor on over 1000 deal related projects covering licensing, mergers, acquisitions, divestments, and joint venture activities for companies world-wide.

PharmaVentures’ deep bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes it uniquely placed to support business in all aspects of deal making and strategic planning. PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.

PharmaVentures’ services include:

  • M&A (divestments, mergers, acquisitions, and strategic transactions)
  • Licensing (in and out licensing)
  • Fundraising Support
  • Strategy (commercialisation, deal strategy, due diligence, market entry)
  • Valuation and Positioning (licensing, M&A, and fundraising)
  • Pricing and Market Access: https://www.pharmaventures.com/pricing-and-market-access/ 

NOTE: This Press release is issued by PharmaVentures Limited, whose wholly owned subsidiary PharmaVentures Capital Limited is authorised and regulated by the Financial Conduct Authority (741356). This communication is for information purposes only and does not constitute an offer or solicitation to purchase or engage in any investment products, securities or services and should not be deemed as such.

For more details, visit https://www.pharmaventures.com

Ralph Hughes joins PharmaVentures to lead Pricing and Market Access practice

How South Korea is an exciting prospect for the world’s life sciences industry

To remain competitive and to take advantage of the latest innovations, life science companies can’t afford to ignore opportunities in South Korea.

PharmaVentures has successfully completed over 30 projects for South Korean biotechs and pharma companies over the last 5 years and is recognised as a leading western transaction advisory firm in the region.

In this white paper, we look at the significant innovative drug development that has taken place within South Korea during the last decade, and how we can use our experience in this area to help Western pharma and biotech companies meet their pipeline needs by accessing the companies at the cutting edge of our industry.

How South Korea is an exciting prospect for the world’s life sciences industry

Download Request